404 related articles for article (PubMed ID: 16788045)
1. Trafficking of Alzheimer's disease-related membrane proteins and its participation in disease pathogenesis.
Suzuki T; Araki Y; Yamamoto T; Nakaya T
J Biochem; 2006 Jun; 139(6):949-55. PubMed ID: 16788045
[TBL] [Abstract][Full Text] [Related]
2. [Advances in molecular biology and clinical study of amyloid precursor protein for Alzheimer's disease].
Xu BG; Wu X
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2004 Apr; 26(2):201-9. PubMed ID: 15171563
[TBL] [Abstract][Full Text] [Related]
3. Enhanced accumulation of tau in doubly transgenic mice expressing mutant betaAPP and presenilin-1.
Samura E; Shoji M; Kawarabayashi T; Sasaki A; Matsubara E; Murakami T; Wuhua X; Tamura S; Ikeda M; Ishiguro K; Saido TC; Westaway D; St George Hyslop P; Harigaya Y; Abe K
Brain Res; 2006 Jun; 1094(1):192-9. PubMed ID: 16713590
[TBL] [Abstract][Full Text] [Related]
4. [Recent advances in Alzheimer's disease research--amyloid precursor protein trafficking, processing, and mutations in Alzheimer's disease linked genes].
Fukatsu R; Tsuzuki K; Hayashi Y; Takamaru Y; Sasaki N; Yoshida T; Hatakeyama Y; Fuji N; Takahata N
Hokkaido Igaku Zasshi; 1997 Jan; 72(1):3-11. PubMed ID: 9086357
[TBL] [Abstract][Full Text] [Related]
5. Brain site-specific gene expression analysis in Alzheimer's disease patients.
Yokota T; Mishra M; Akatsu H; Tani Y; Miyauchi T; Yamamoto T; Kosaka K; Nagai Y; Sawada T; Heese K
Eur J Clin Invest; 2006 Nov; 36(11):820-30. PubMed ID: 17032350
[TBL] [Abstract][Full Text] [Related]
6. Carboxyl-terminal fragments of presenilin-1 are closely related to cytoskeletal abnormalities in Alzheimer's brains.
Tomidokoro Y; Ishiguro K; Igeta Y; Matsubara E; Kanai M; Shizuka M; Kawarabayashi T; Harigaya Y; Kawakatsu S; Ii K; Ikeda M; St George-Hyslop PH; Hirai S; Okamoto K; Shoji M
Biochem Biophys Res Commun; 1999 Mar; 256(3):512-8. PubMed ID: 10080929
[TBL] [Abstract][Full Text] [Related]
7. Amyloid precursor protein cytoplasmic domain with phospho-Thr668 accumulates in Alzheimer's disease and its transgenic models: a role to mediate interaction of Abeta and tau.
Shin RW; Ogino K; Shimabuku A; Taki T; Nakashima H; Ishihara T; Kitamoto T
Acta Neuropathol; 2007 Jun; 113(6):627-36. PubMed ID: 17431643
[TBL] [Abstract][Full Text] [Related]
8. Deposition of mouse amyloid beta in human APP/PS1 double and single AD model transgenic mice.
van Groen T; Kiliaan AJ; Kadish I
Neurobiol Dis; 2006 Sep; 23(3):653-62. PubMed ID: 16829076
[TBL] [Abstract][Full Text] [Related]
9. Non-tau based neuronal degeneration in Alzheimer's disease -- an immunocytochemical and quantitative study in the supragranular layers of the middle temporal neocortex.
van de Nes JA; Nafe R; Schlote W
Brain Res; 2008 Jun; 1213():152-65. PubMed ID: 18455153
[TBL] [Abstract][Full Text] [Related]
10. Phosphorylated tau in neuritic plaques of APP(sw)/Tau (vlw) transgenic mice and Alzheimer disease.
Pérez M; Morán MA; Ferrer I; Avila J; Gómez-Ramos P
Acta Neuropathol; 2008 Oct; 116(4):409-18. PubMed ID: 18679696
[TBL] [Abstract][Full Text] [Related]
11. Amyloid, dementia and Alzheimer's disease.
Hyman BT; Tanzi RE
Curr Opin Neurol Neurosurg; 1992 Feb; 5(1):88-93. PubMed ID: 1623244
[TBL] [Abstract][Full Text] [Related]
12. Cytoskeletal alterations differentiate presenilin-1 and sporadic Alzheimer's disease.
Woodhouse A; Shepherd CE; Sokolova A; Carroll VL; King AE; Halliday GM; Dickson TC; Vickers JC
Acta Neuropathol; 2009 Jan; 117(1):19-29. PubMed ID: 19015863
[TBL] [Abstract][Full Text] [Related]
13. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics.
Hardy J; Selkoe DJ
Science; 2002 Jul; 297(5580):353-6. PubMed ID: 12130773
[TBL] [Abstract][Full Text] [Related]
14. A transgenic rat model of Alzheimer's disease with extracellular Abeta deposition.
Flood DG; Lin YG; Lang DM; Trusko SP; Hirsch JD; Savage MJ; Scott RW; Howland DS
Neurobiol Aging; 2009 Jul; 30(7):1078-90. PubMed ID: 18053619
[TBL] [Abstract][Full Text] [Related]
15. Axonopathy in an APP/PS1 transgenic mouse model of Alzheimer's disease.
Wirths O; Weis J; Szczygielski J; Multhaup G; Bayer TA
Acta Neuropathol; 2006 Apr; 111(4):312-9. PubMed ID: 16520967
[TBL] [Abstract][Full Text] [Related]
16. [Pathogenesis of Alzheimer's disease].
Alegre M; Noé E; Luquin MR
Rev Med Univ Navarra; 1997; 41(1):46-57. PubMed ID: 9527714
[TBL] [Abstract][Full Text] [Related]
17. High sensitivity analysis of amyloid-beta peptide composition in amyloid deposits from human and PS2APP mouse brain.
Güntert A; Döbeli H; Bohrmann B
Neuroscience; 2006 Dec; 143(2):461-75. PubMed ID: 17008022
[TBL] [Abstract][Full Text] [Related]
18. Stress proteins in Alzheimer's disease.
Smith RC; Rosen KM; Pola R; Magrané J
Int J Hyperthermia; 2005 Aug; 21(5):421-31. PubMed ID: 16048839
[TBL] [Abstract][Full Text] [Related]
19. X-34 labeling of abnormal protein aggregates during the progression of Alzheimer's disease.
Ikonomovic MD; Abrahamson EE; Isanski BA; Debnath ML; Mathis CA; Dekosky ST; Klunk WE
Methods Enzymol; 2006; 412():123-44. PubMed ID: 17046656
[TBL] [Abstract][Full Text] [Related]
20. Stage-correlated distribution of type 1 and 2 dystrophic neurites in cortical and hippocampal plaques in Alzheimer's disease.
Thal DR; Härtig W; Schober R
J Hirnforsch; 1998; 39(2):175-81. PubMed ID: 10022341
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
